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Objectives: In our systematic review, we assessed past and current practice of patient-reported outcome (PRO) measurement
in cancer randomized, controlled trials (RCTs).
Methods: We included RCTs with PRO endpoints evaluating conventional medical treatments, conducted in patients with the
most prevalent solid tumor types (breast, lung, colorectal, prostate, bladder, and gynecological cancers) and either published
in 2004 to 2018 or registered on clinicaltrials.gov and initiated in 2014 to 2019. Frequency of use of individual PRO measures
was assessed overall, over time, and by cancer site.
Results: Screening of 42 095 database records and 3425 registered trials identified 480 published and 537 registered trials
meeting inclusion criteria. Among published trials, the European Organisation for Research and Treatment of Cancer (EORTC)
measures were used most often (54.8% of trials), followed by the Functional Assessment of Chronic Illness Therapy (FACIT)
measures (35.8%), the EQ-5D (10.2%), the SF-36 (7.3%), and the MD Anderson Symptom Inventory (MDASI; 2.5%). Among
registered trials, the EORTC measures were used in 66.1% of the trials, followed by the FACIT measures (25.9%), the EQ-5D
(23.1%), the SF-36 (4.8%), the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events
(PRO-CTCAE; 2.2%), the Patient-Reported Outcomes Measurement Information System (PROMIS) measures (1.7%), and the
MDASI measures (1.1%).
Conclusion: The PRO measures most frequently used in RCTs identified in our review differ substantially in terms of content
and domains, reflecting the ongoing debate among the scientific community, healthcare providers, and regulators on the type
of PRO to be measured. Current findings may contribute to better informing the development of an internationally agreed
core outcome set for future cancer trials.
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Patient-reported outcomes (PROs), such as health-related
quality of life (HRQOL), functional health, and symptom burden,
are now frequently used in clinical trials to complement tradi-
tionally used cancer outcomes such as overall and progression-
free survival. Patient-reported outcomes can provide valuable
information from the patients’ perspectives on the clinical bene-
fits, safety, and tolerability of cancer treatments.1,2
Incorporation of rigorous assessment of PROs into cancer trials
is also of critical importance for the international regulatory and
health policy community. Indeed, the value of incorporating high-
quality PRO data into regulatory decision-making process has also
been recently well outlined.3
In 2014, a US National Cancer Institute (NCI)–driven initiative
proposed that symptom endpoints should be used for evaluating
new therapies from the patients’ perspectives across cancer15 - see front matter Copyright ª 2020, ISPOR–The Professional Society for
cess article under the CC BY license (http://creativecommons.org/licenses/bclinical trials.4 The US Food and Drug Administration (FDA) sub-
sequently published a suggested core set of concepts for cancer
trials that recommended the addition of physical function5-7 to
provide context for the functional impact of symptomatic adverse
events and disease-related symptoms. The FDA suggests this as an
initial focus for defining patient-reported endpoints in cancer
trials but states that “other aspects of the patient experience may
also be important to measure, and all submitted PRO data will be
taken into account during product review.”8 Taking a somewhat
different approach, the European Medicines Agency more explic-
itly encourages taking a broader perspective, including di-
mensions of HRQOL.9,10
A number of measures are available and are widely used to
assess PROs in cancer randomized, controlled trials (RCTs). Most
have been developed after rigorous procedures11-13 to ensure that
they cover content that is relevant to clinicians and patients and
meet standards set for measurement reliability and validity.14Health Economics and Outcomes Research. Published by Elsevier Inc. This is an
y/4.0/).
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validity are often comparably high for the most commonly used
PRO measures, they may differ substantially with regard to the
type and number of health domains covered.
As discussed at a recent FDA–American Society of Clinical
Oncology workshop: “the international community is also inter-
ested in identifying core clinical outcome sets that can be used to
facilitate registries, pragmatic trials and other data sources that
can be used to inform international regulatory, payer, provider and
patient decision making.”15 To achieve this, it is important to
understand the current practice of international PRO data collec-
tion, since it may reflect a certain degree of consensus on what
health domains to assess in clinical trials.
Therefore, we investigated past and current practice of PRO
measurement in cancer RCTs, conducting a systematic literature
review covering studies published between 2004 and 2018 and an
analysis of registered trials initiated during the years 2014 to 2019.
We assessed in detail the frequency over time with which specific
PROmeasures have been used overall, as well as by funding source
and by cancer site.Methods
Identification of PRO Measures Captured in Completed
Cancer RCTs Published Between 2004 and 2018
Data were gathered through the Patient-Reported Outcome
Measurements Over Time In ONcology (PROMOTION) registry
(promotion.gimema.it), which is a web-based password-protected
database (REDCap16) that systematically collects several types of
information on published cancer RCTs with a PRO component
(either as primary or secondary/exploratory endpoint). This
database currently contains information on 918 RCTs, conducted
across several cancer malignancies, that were published from
January 2004 to February 2019. Details on the standard method-
ology for the systematic identification of eligible studies, as well as
data extracted from RCTs that populate the database, have been
previously reported.17,18 Briefly, RCTs comparing conventional
medical treatment modalities and enrolling at least 50 patients
(combined arms) are systematically identified, mainly through
PubMed/Medline, and using ad hoc key searching strategies for
each cancer disease site. Studies evaluating screening programs,
complementary or alternative medicines, psychosocial in-
terventions, or exercise and behavioral interventions are not
considered for inclusion in the database. A double-blind data
entry procedure is implemented to extract a set of predefined
information (from each eligible RCT) by at least 2 independent
reviewers, and a third one is consulted in case of disagreement.
Information extracted includes RCT characteristics, PRO design
and PRO questionnaires used, risk of bias, and accuracy of PRO
reporting as defined by the International Society for Quality of Life
Research criteria.19 For the purpose of this analysis, we selected
RCTs conducted in the following 6 most frequent cancer sites:
breast, lung (ie, non-small-cell lung cancer), colorectal, bladder,
prostate, and gynecological cancers, which were all published
between January 2004 and December 2018.
Identification of PRO Measures Included in Cancer RCTs
Registered as Starting Between 2014 and 2019
Trials registered on the clinicaltrials.gov trial registry were
identified through use of a search strategy that was harmonized
with the criteria for selecting trials for the PROMOTION registry,
with the exceptions being the time period (registered trials
starting between January 1, 2014, and June 30, 2019) and theinclusion criteria for PRO measures. Key searching strategies used
for article identification in the PROMOTION Registry are available
from the authors. We selected trials starting after January 2014
based on the assumption that trials starting earlier would most
likely already be included in the PROMOTION registry.
Although the PROMOTION registry includes RCTs reporting
results for any PRO measure, we limited the clinicaltrial.gov search
to RCTs using the 5 PRO measures most frequently found in the
PROMOTION registry: EORTC (European Organisation for Research
and Treatment of Cancer)20 measures, EQ-5D,21 FACIT (Functional
Assessment of Chronic Illness Therapy),12 MDASI (MD Anderson
Symptom Inventory),22 and SF-36.23 Also included were 2 mea-
sures developed more recently, which have been discussed at a
recent American Society of Clinical Oncology–FDA workshop:15
the PRO-CTCAE (Patient-Reported Outcomes version of the Com-
mon Terminology Criteria for Adverse Events24) and the PROMIS
(Patient-Reported Outcomes Measurement Information Sys-
tem25). For a short description of these PRO measures and the
search terms used for their identification via the “Outcome”
search field of clinicaltrials.gov, please see Table 1.
All selection criteria were evaluated independently by 2 re-
viewers, with consensus discussions in case of disagreements. In
addition, the 2 reviewers checked the full registration information
on the clinicaltrials.gov website to verify that the trials retrieved
through our search strategy included the relevant PRO measures.
Data Analysis
The use of the PRO measures is described with absolute and
relative frequencies (overall and by cancer site) for the 5 most
commonly found measures in the PROMOTION registry, and for
the 7 measures included in the analysis of registered trials. For
both published and registered trials, the frequency with which the
individual PRO measures were used was calculated using the total
number of trials with any of the PROmeasures under investigation
(please see Table 1) as the denominator, and expressed as a per-
centage. We also report frequencies of trials that used the core
questionnaires, the FACT-G and the EORTC QLQ-C30, with or
without supplemental disease-specific modules (including
symptom indices).
For evaluating time trends, we present the relative frequency
(percentage) of use for each measure over time. Percentages were
calculated relative to the number of trials in the respective pe-
riods. Industry involvement was investigated by comparing the
frequency of use of the PRO measures between studies with or
without industry funding.Results
Analysis of Published RCTs (2004-2018)
We screened 42 095 PROMOTION registry records to identify
2654 full-text articles for review. In total, 646 cancer RCTs pub-
lished between 2004 and 2018 were included in the PROMOTION
registry and met the inclusion criteria (see Appendix Figure 1 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.202
0.11.004).
Of these 646 trials, 480 trials (74.3%) used one of the PRO
measures under investigation (see Table 1). In order of frequency,
these 480 published trials were conducted in breast cancer (146
trials, 30.4%), lung cancer (111 trials, 23.1%), colorectal cancer (76
trials, 15.8%), prostate cancer (70 trials, 14.6%), gynecological
cancers (69 trials, 14.4%), and bladder cancer (8 trials, 1.7%). In
these 480 trials. The EORTC measures were used in 263 trials
(54.8%), the FACIT measures in 172 trials (35.8%), the EQ-5D in 49
Table 1. Description of PRO measures and search terms used for identifying relevant cancer RCTs on www.clinicaltrials.gov.
PRO measure Description Search terms*
EORTC (European Organisation for
Research and Treatment of Cancer)
measures
The EORTC measures comprise the
cancer-specific QLQ-C30 (Quality of Life
Questionnaire Core 3020;) a
multidimensional HRQOL core measure
that assesses 5 functional health
domains, 9 symptom domains and global
quality of life, and a number of
questionnaire modules specific to certain
cancer diagnoses or symptoms.
"eortc" OR "qlq" OR "c30" OR "qlqc30" OR
"c-30" OR "core30" OR "core-30" OR
"qlq30"
EQ-5D (Euroqol 5-Dimensions) The generic EQ-5D21 is a health utility
measure covering 5 health domains and
is frequently used in health economics to
calculate quality-adjusted life-years.
"EQ-5D" OR "Euroqol" OR "EQ5D"
FACIT (Functional Assessment of Chronic
Illness Therapy)
The FACIT system includes the cancer-
specific FACT-G (Functional Assessment of
Cancer Therapy – General) for the
assessment of four HRQOL domains
(physical, functional, emotional, and
social well-being) and questionnaire
modules for specific diagnoses and
symptoms.12
FACIT OR "fact" OR "functional
assessment" OR "function assessment"
OR "cancer therapy-general" OR "FAACT"
MDASI (MD Anderson Symptom
Inventory)
The MDASI core questionnaire22 assesses
the severity of 13 symptoms and their
interference with different aspects of
daily living. Next to the core
questionnaire several modules are
available.
"MDASI" OR "MDADI" OR "Anderson" OR
"MD"
PRO-CTCAE (Patient-Reported Outcomes
version of the Common Terminology
Criteria for Adverse Events)
The PRO-CTCAE is a self-report version of
the cancer-specific Common Terminology
Criteria for Adverse Events.24




PROMIS25 provides item banks for the
assessment of key health domains
relevant across medical fields.
"promis" OR "Patient Reported Outcomes
Measurement Information System"
SF-36 (Short-Form 36) The SF-36 (23; and its SF-12 short-form) is
a generic health questionnaire that is
applied across medical fields to assess
various HRQOL domains.
"SF-36" OR "SF36" OR "SF-12" OR "SF12"
OR "SF-6D" OR "SF6D" OR "Short-form"
OR "Shortform" OR "MOS"
PRO indicates patient-reported outcome.
*Please note that only nonredundant search terms are reported here (ie, search terms that increased the number of identified trials).
SYSTEMATIC LITERATURE REVIEW 587trials (10.2%), the SF-36 in 35 trials (7.3%), and the MDASI in 12
trials (2.5%).
The EORTC QLQ-C30 and FACT-G core questionnaires were
supplemented with condition- or symptom-specific questionnaire
modules in 55.5% and 94.8% of trials, respectively. The SF-36 wasTable 2. Frequency of PRO measures used in randomized clinical tr








Note. Percentages are given relative to the number of trials published between 2004
EORTC indicates European Organisation for Research and Treatment of Cancer; FA
Symptom Inventory; PRO, patient-reported outcome.used in combination with the FACIT measures in 6 trials, with the
EORTC measures in 3 trials, and with the MDASI in 2 trials.
Out of the 480 published trials, 284 (59.2%) trials were (at least
in part) funded by industry, whereas 196 (40.8%) were not. The
EORTC measures were used in 56.1% of the non-industry-fundedials by cancer site.
FACIT EQ-5D SF-36 MDASI
41.1% 5.5% 8.2% 7.5%
34.2% 15.3% 1.8% 0.0%
47.1% 7.1% 11.4% 0.0%
17.1% 15.8% 13.2% 1.3%
36.2% 10.1% 4.3% 0.0%
37.5% 0.0% 0.0% 0.0%
35.8% 10.2% 7.3% 2.5%
and 2018 that used one of the PRO measures under investigation (N = 480).
CIT, Functional Assessment of Chronic Illness Therapy; MDASI, MD Anderson
588 VALUE IN HEALTH APRIL 2021trials and 53.9% of the trials with industry funding. For the other
PRO measures, these frequencies were as follows: FACIT measures
30.1% (non-industry) versus 39.8% (industry), SF-36 12.8% (non-
industry) versus 3.5% (industry), EQ-5D 6.1% (non-industry) versus
13.0% (industry), and MDASI 4.1% (non-industry) versus 1.4% (in-
dustry). The EORTC QLQ-C30 core questionnaire was used in
combination with modules in 54.9% of non-industry trials and
56.4% of industry-funded trials. For the FACT-G modules were
used in 94.9% of non-industry trials and 94.7% of industry trials.
Across cancer sites, the EORTC measures were used most
frequently in colorectal cancer trials (68.4% of trials) and least
often in prostate cancer trials (47.1%). The FACIT measures were
administered most often in prostate cancer trials (47.1%) and least
often in colorectal cancer trials (17.1%). Further details are pro-
vided in Table 2.
Analyzing the time trend for the 3 most frequently used PRO
measures, we found that the EORTC measures were used in 64.4%
of the trials in the period 2004-2006, 50.0% of the trials in the
period 2010-2012, and 51.9% in the most recent period (2016-
2018). The EQ-5D showed a strong increase in use over time
(frequency #4.0% for 2004-2009 and 21.0% for 2016-2018). Fre-
quency of the FACIT measures use increased over time from 27.3%
of trials in 2004-2006 to 41.8% in 2013-2015, and 35.8% most
recently (2016-2018). Please see Figure 1 for further details.
Analysis of Registered RCTs (2014-2019)
Our review of clinicaltrials.gov identified 3425 potentially
eligible trials and after applying all exclusion criteria, 537 were
included in the final analysis (see Appendix Figure 2 in Supple-
mental Materials found at https://doi.org/10.1016/j.jval.2020.11.
004).Figure 1. Time trend for the frequency of patient-reported outcome
controlled trials (RCTs) in the Patient-Reported Outcomes Measuremen
given relative to the number of trials per period that used at least 1
EORTC FACIT EQ
2004-2006 64,6% 27,3% 4
2007-2009 57,0% 34,9% 3
2010-2012 50,0% 38,5% 8
2013-2015 50,9% 41,8% 14











2004-2006 2007-2009 2010-2Of 537 included trials, 137 (25.5%) were conducted in patients
with lung cancer, 127 (23.6%) in patients with breast cancer, 86
(16.0%) in patients with colorectal cancer, 79 (14.7%) in patients
with gynecological tumors, 71 (13.2%) in patients with prostate
cancer, and 37 (6.9%) in patients with bladder cancer. The EORTC
measures were used in 355 trials (66.1%), the FACIT measures in
139 trials (25.9%), the EQ-5D in 124 trials (23.1%), the SF-36 in 26
trials (4.8%), the PRO-CTCAE in 12 trials (2.2%), the PROMIS mea-
sures in 9 trials (1.7%), and the MDASI measures in 6 trials (1.1%).
The EORTC QLQ-C30 and FACT-G were supplemented with
condition/symptom-specific questionnaires modules in 61.4% and
95.0% of trials, respectively. The SF-36 was used in combined with
the FACIT measures in 3 trials, and with the EORTC measures in 2
trials.
Of the 537 registered trials, 278 (51.8%) trials were funded
without industry involvement, and 259 (48.2%) were funded, at
least in part, by industry. The EORTC measures were used in 59.7%
of the non–industry-funded trials and 73.0% of the trials with
industry funding. For the other PRO measures this ratio was as
follows: FACIT measures 27.7% (non-industry) versus 23.9% (in-
dustry), SF-36 7.6% (non-industry) versus 1.9% (industry), EQ-5D
22.3% (non-industry) versus 23.9% (industry), PROMIS 2.9% (non-
industry) versus 0.4% (industry), PRO-CTCAE 2.9% (non-industry)
versus 1.5% (industry), and MDASI 0.4% (non-industry) versus 1.9%
(industry). For the EORTC QLQ-C30 additional questionnaire
modules were used in 63.3% of non-industry trials and 59.8% of
industry-funded trials. The FACT-G was supplemented in 94.8% of
non-industry trials and in 95% of industry-funded trials. For those
trials with industry involvement, the type of sponsor and funding
source were congruent for all but 5 trials, and thus no additional
analysis was conducted by sponsor.(PRO) measures used most frequently in cancer randomized
ts Over Time In ONcology (PROMOTION) registry. Percentages are









SYSTEMATIC LITERATURE REVIEW 589Across cancer sites, the EORTC measures were used most
frequently in colorectal cancer trials (75.6% of trials) and least
often in prostate cancer trials (42.3%). The FACIT measures were
administered most often in prostate cancer trials (46.5%) and least
often in colorectal cancer trials (12.8%). Further details are given in
Table 3.
An analysis of trends over time between January 2014 and June
2019 showed an increase in published trials using the EORTC
measures (lowest frequency in 2015: 56.8%; highest frequency in
2018: 74.8%), a decrease for the FACIT (highest in 2015: 32.9%;
lowest in 2019: 19.8%), and a fluctuating use of the EQ-5D (ranging
from 19.3% in 2018 to 27.0% in 2015). For details, please see
Figure 2. The percentage of trials supplementing the EORTC QLQ-
C30 with a questionnaire module decreased from 70.8% in 2014 to
55.2% in 2019. For the FACT-G this proportion fluctuated between
90.9% in 2015 and 100% in 2014.Table 3. Frequency of PRO measures used in registered randomize
Cancer site No. of trials EORTC FACIT EQ
Lung 137 70.1% 20.4% 24
Breast 127 66.1% 27.6% 21
Colorectal 86 75.6% 12.8% 20
Gynecological 79 67.1% 30.4% 20
Prostate 71 42.3% 46.5% 26
Bladder 37 73.0% 21.6% 27
Total 537 66.1% 25.9% 23
Note. Percentages are given relative to the number of trials starting between January
EORTC indicates European Organisation for Research and Treatment of Cancer; FA
Symptom Inventory; PRO, patient-reported outcome; PRO-CTCAE, Patient-Reported
PROMIS, Patient-Reported Outcomes Measurement Information System.
Figure 2. Time trend of the frequency of patient-reported outcome
are given relative to the number of trials per year that used any of th
EORTC FACIT EQ-5D S
2014 60,8% 32,9% 21,5% 6
2015 56,8% 29,7% 27,0% 8
2016 67,1% 27,1% 20,0% 3
2017 64,9% 28,7% 25,5% 4
2018 74,8% 20,2% 19,3% 1












*only January to JuneDiscussion
Our review indicates that the EORTC measures were the most
frequently used PRO tools in published and registered RCTs of
most common solid cancers, followed by the FACIT measures and
the EQ-5D. The analysis of published RCTs showed a clear increase
in the use of the EQ-5D between 2004 and 2018 and a mostly
stable frequency in the more recently registered trials.
By analyzing 2 types of databases we were able to generate a
detailed picture of past and current practice of PRO instrument
selection in cancer RCTs. When interpreting our results on pub-
lished trials, it should be taken into account that the decision to
use a certain PRO measure usually has been made several years
prior to publication of study results.26 Therefore, we considered it
important to extend our search to clinicaltrials.gov and also to
assess registered trials starting before June 2019 to gain a mored clinical trials by cancer site.
-5D SF-36 PRO-CTCAE PROMIS MDASI
.8% 2.2% 2.2% 0.7% 2.9%
.3% 1.6% 3.1% 2.4% 0.8%
.9% 14.0% 1.2% 1.2% 0.0%
.3% 3.8% 2.5% 1.3% 1.3%
.8% 7.0% 1.4% 4.2% 0.0%
.0% 2.7% 2.7% 0.0% 0.0%
.1% 4.8% 2.2% 1.7% 1.1%
2014 and June 2019 and using any of the 7 PRO measures (N = 537).
CIT, Functional Assessment of Chronic Illness Therapy; MDASI, MD Anderson
Outcomes version of the Common Terminology Criteria for Adverse Events;
(PRO) measures registered on www.clinicaltrials.gov. Percentages
e 7 PRO measures under investigation.
F-36 MDASI PROMIS PRO-CTCAE
,3% 1,3% 1,3% 1,3%
,1% 4,1% 0,0% 0,0%
,5% 1,2% 2,4% 2,4%
,3% 0,0% 1,1% 2,1%
,7% 0,0% 0,0% 4,2%
,0% 1,2% 5,8% 2,3%
stered cancer RCTs over time
2017 2018 2019*
590 VALUE IN HEALTH APRIL 2021contemporary perspective on planned use in registered studies. As
a consequence of the time lag betweenwriting of the trial protocol
and publication of trial results, the related new PROMIS measures
(published first in 200927) and the PRO-CTCAE (published first in
201524) were not used in any of the published trials, while a
number of studies using these measures were identified in our
search of www.clinicaltrials.gov. In addition, both databases differ
regarding coverage. Whereas the PROMOTION registry only covers
trials with published PRO results and is therefore prone to pub-
lication bias,26 the analysis of clinicaltrials.gov does not include
trial protocols that are registered in other registries or not regis-
tered at all.
Our study has several limitations that should be noted. We
focused on only the most common cancer types and restricted the
selection of studies to RCTs. In addition, we included only tradi-
tional medical treatments and did not consider behavioral or
psychosocial interventions. Because the choice of a PRO measure
also depends on the type of clinical benefit or harm expected from
an intervention, frequencies of the use of PRO measures may differ
across different types of interventions and study designs. How-
ever, our results are consistent with other studies on the fre-
quency of the use of PRO measures in oncology that focused on
specific measures,28 or routine cancer clinical practice.29 For trials
submitted to regulatory authorities,9,30 frequencies for the EORTC
and FACIT measures are comparable to our findings, whereas the
EQ-5D is used more frequently, in about half of such trials.
Our review also has notable strengths. To the best of our
knowledge, this is the first and largest evidence-based review of
the use of PROmeasures stemming from a rigorous and systematic
assessment of RCTs, both published and ongoing. This provides a
broad picture of past and current practice with regard to PRO
assessment in clinical trials in oncology.
In most cases, the decision to use a certain PRO measure in a
cancer trial reflects conceptual considerations such as whether or
not to conduct a multidimensional HRQOL assessment, to measure
symptom burden only, or to focus on broader health domains. It is
noteworthy that the majority of trials in our analysis used either
the EORTC measures, the FACIT measures, the EQ-5D, or the SF-36,
all of which are multidimensional questionnaires that are not
limited to physical functioning or somatic symptoms, but also
include broad HRQOL concepts and assess emotional, social, and
(role) functional aspects of health. We found that the FACT-G core
questionnaire was supplemented with a disease-specific FACIT
module in about 95% of registered trials, whereas this was the case
for only 61% of the registered trials using the EORTC QLQ-C30. This
may reflect that the EORTC core questionnaire already includes
key cancer symptoms in addition to the functional health do-
mains, whereas the FACIT core questionnaire focuses more on
functional health with symptoms being assessed within its sub-
scales and the additional disease-specific modules and symptom
indices. More recently, item libraries with supplementary items on
specific health issues have been made available for both the
EORTC and the FACIT measurement systems to allow for a more
flexible assessment approach. The flexibility of these item libraries
may be particularly beneficial when evaluating new treatment
types with toxicity profiles that differ from traditional treatments.
In general, our results indicate that past and current practice of
PRO assessment in clinical trials frequently includes health do-
mains that go beyond those recommended by the NCI-initiative4
and suggested as initial focus by FDA representatives.8 The
increasing use of the EQ-5D may reflect that health utility data are
gaining importance in the context of health economics and for
reimbursement of treatment costs.31,32 PROMIS measures, target-
ing specific symptoms and functional domains, are seeing a sig-
nificant rise in use, especially as multiple language versions arebecoming available. Also, it is expected that newer measures such
as the PRO-CTCAE will play an increasingly important role in the
assessment of tolerability in future studies.8 This may, in part,
reflect an increasing popularity of item libraries and the impact of
the views of regulatory authorities. Frequency of use, in and of
itself, does not necessarily provide guidance about which PRO
measures should be used in future RCTs. However, documentation
of the frequency of use of PRO measures in this review may serve
as a starting point for more detailed considerations on how best to
match specific research questions with available PRO measures.
In conclusion, within the current evolving scenario of recently
published PRO measurement guidelines and recommendations,
our findings provide a historical and current perspective on PRO
measures most frequently used in RCTs conducted across the most
common solid tumor malignancies. Our research has identified
the most commonly used PRO measures in (inter)national cancer
trials and thus provides information on the scope and the type of
health domains that have been assessed in cancer RCTs. We
believe that this information can help inform the development of
an internationally agreed core outcome set to be recommended
for use in future cancer trials. In addition, newer emerging mea-
sures such as the PRO-CTCAE and the FACIT (https://wizard.facit.
org/) and EORTC item library (https://www.eortc.be/itemlibrary/)
should also be considered to provide an estimate of treatment
tolerability. Similar analyses performed in cancer research settings
other than RCTs will be important to further expand our knowl-
edge of current practice of PRO measurement approaches in the
wider cancer arena.Supplemental Materials
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